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Molecular and diagnostic clinical virology
in real time
Bert Niesters’ enthusiastic review of molecular
methods in diagnostic virology [1] makes many
valid and useful points, but omits some important
viruses and is over-dismissive of the value of cell
culture. His Table 2 lists viruses for which
in-house molecular tests should be developed,
but omits rotaviruses, parainfluenza viruses and
flaviviruses. Vaccines against rotaviruses are
under trial and tests for them will be essential in
any evaluation of their efficacy. Parainfluenza
viruses are important respiratory viruses, types 1
and 2 frequently active in the winter, and type 3
active in the spring and summer. If global warm-
ing progresses, flaviviruses, such as West Nile
virus, which are prevalent in the tropics and have
already caused epidemics in the USA, will become
commonplace in temperate climes. Since the re-
view was written, the SARS coronavirus has also
emerged and its epidemic potential would also
now rate a special mention.
Moreover, the unqualified entry of ‘adenovi-
ruses’ gave me concern, and highlights the point
Dr Niesters himself makes about the extra sensi-
tivity of molecular methods and the need to
evaluate the significance of finding amplified
DNA or RNA. Adenoviruses were discovered
originally in explant organ cultures of apparently
normal tonsils in which they had persisted [2],
especially in children, and may not therefore be
causing disease. Both typing and quantification is
necessary for such positive results [3]. In addition,
adenoviruses of types 40 and 41 have been
implicated in diarrhoeal disease; their presence
in the nasopharynx might be revealed by ampli-
fication, but the significance of such a finding
is unknown. Hence, some sero ⁄ genotyping of
adenoviruses is essential.
The availability of high-quality cell culture as
part of diagnostic virology will remain essential
as long as new viruses or variants of old viruses
(such as novel influenza A viruses) continue to
appear. We must have a catch-all system which
does not depend on primers prepared previously,
or other reagents. Although random primers may
pick up new viruses, this is not guaranteed, and a
negative result does not mean that no virus is
present. Personally, I would wish to add electron
microscopy (EM) as another catch-all tech-
nique—morphology tells us what sort of virus is
present, and other properties can be predicted
with considerable confidence from knowing what
it looks like. Nonetheless, both cell culture and
EM depend on practised personal skills, and both
techniques must be used regularly and consis-
tently if they are to work reliably. It seemed to me
that Dr Niesters felt that cell culture could be set
up ‘as-and-when’ it was needed, and might, or
even should, be phased out in the near future.
This view is mistaken, and it should also be
emphasised that cell culture must be in continu-
ous and routine use to demonstrate that it can,
and is, isolating viruses. Running cell culture is a
skill analogous to top-class sport or music—prac-
tice makes (more) perfect, while absence of
practice leads to disaster.
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R E S P O N S E F R O M D R N I E S T E R S
Professor Madeley’s comments address some
points raised during recent discussions on how
molecular testing and virus culture should be
dealt with in the routine clinical virological
laboratory. In principle, we do not disagree about
this. The discussion should actually be directed
towards the following points:
 Should we use molecular diagnostics in clin-
ical virology by selecting primers and probes to
detect all possible viruses? Definitely not, and
Table 2 in my review was intended more to
indicate the fact that, unfortunately, only a few
commercially validated tests are available, and
that this number has not increased significantly in
the last few years. However, in the laboratory,
tests are needed for a growing number of viral
targets (whether such tests are based on molecular
testing, serology or virus culture is not relevant).
The implementation of tests for Epstein–Barr virus
has been successful in our hospital for allogeneic
bone marrow transplant patients, and the value of
adenovirus detection in the same group of young
patients has also been demonstrated [4].
 It is important that molecular testing should
be quantitative, although one can argue that this
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is not always of clinical value. However, the
example of detecting adenovirus in the nasophar-
ynx, as mentioned by Professor Madeley, dem-
onstrates the importance of quantitative results.
The technology is available, and the information
is needed to understand the importance of viral
load in relation to clinical outcome. The recent
detection of almost 9% of double infections in
respiratory samples, as reported by several
groups at the recent meeting of the European
Society for Clinical Virology in Copenhagen,
strengthens the need for and value of this quan-
titative information.
 The list in Table 2 is far from complete, but
it is not realistic to extend it to include all
known viruses. I agree that parainfluenza vir-
uses should be on the shortlist, but other
important viruses are also missing. Technology
is developing fast, and it is becoming possible
to combine a positive and quantitative signal
with typing for a growing number of viruses,
including enteroviruses (and parechovirus) and
adenoviruses.
 The discussion on the position of virus
culture is still ongoing. We both agree that
high-quality cell culture-based facilities are nee-
ded, not only to obtain epidemiologically rele-
vant strains, but also to detect ‘new’ and
emerging viruses. However, this is a problem
for those laboratories that do not have any
culture facilities, or for which transportation of
clinical specimens to the laboratory takes a
relatively long period. Is the molecular diagnos-
tics approach the answer to better clinical virol-
ogy? The answer ‘yes’ is too easy, simply
because the technology itself can be rather
difficult to implement, and information on the
primers and probes needed is often limited with
respect to their clinical performance. Unfortu-
nately, studies that analyse only a limited num-
ber of clinical reference strains and samples are
still in the majority. So, although it is necessary
to remain critical, it cannot be denied that
molecular testing is a significant aid to diagnosis.
 The question of whether virus culture is
obsolete or should be phased out in the future is
also influenced by the fact that there are now
limited numbers of laboratories capable of per-
forming virus culture. The number of laboratories
with EM facilities is even smaller, with a conse-
quent loss of knowledge. I agree with Professor
Madeley in this respect, but while practice makes
(more) perfect, it is important to realise that in a
large number of laboratories, there is already no
practice at all.
In my view, molecular diagnostics has had, and
will continue to have, a great impact in clinical
virology. However, there is still a lot to learn and,
in a routine clinical virology laboratory, molecular
testing, serology and virus culture are the major
cornerstones. The continuation of EM is most in
doubt, and in my own country is limited to those
laboratories that are enthusiastic enough to send
people for training. But without support from the
government, it will be difficult to maintain.
H. G. M. Niesters
Department of Virology,
Erasmus MC,
University Medical Centre Rotterdam,
Dr Molewaterplein 40,
3015 GD Rotterdam,
The Netherlands
E-mail: h.g.m.niesters@erasmusmc.nl
R E F E R E N C E S
1. Niesters HGM. Molecular and diagnostic clinical virology in
real time. Clin Microbiol Infect 2004; 10: 5–11.
2. Rowe WP, Huebner RJ, Gillmore LK et al. Isolation of a
cytopathogenic agent from human adenoids undergoing
spontaneous degeneration in tissue culture. Proc Soc Exp Biol
Med 1953; 84: 570–573.
3. Madeley CR, Peiris JSM, McQuillin J. Adenoviruses. In:
Myint S, Taylor-Robinson D, eds. Viral and other infections of
the human respiratory tract. London: Chapman & Hall, 1995;
169–190.
4. Schilham MW, Claas EC, van Zaane W et al. High levels of
adenovirus DNA in serum correlate with fatal outcome of
adenovirus infection in children with allogeneic stem-cell
transplantation. Clin Infect Dis 2002; 35: 526–532.
472 Clinical Microbiology and Infection, Volume 10 Number 5, May 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 471–472
